Theoretical optimization of Irinotecan-based anticancer strategies in the case of drug-induced efflux

Applied Mathematics Letters

Volumn 24, Issue 7, 2011, Pages 1251-1256

  Ballesta, Annabelle ^a,b,c   Clairambault, Jean ^a,b,c   Dulong, Sandrine ^b,c   Levi, Francis ^b,c  

^a INRIA ROCQUENCOURT   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Anticancer drug; Drug driven transporter induction; Molecular modeling; Pharmacokineticspharmacodynamics; Therapeutics optimization

Indexed keywords

ABC TRANSPORTER; ANTICANCER DRUG; ATP-BINDING CASSETTE TRANSPORTERS; CANCER CELLS; DNA DAMAGES; DRUG COMBINATIONS; DRUG-DRIVEN TRANSPORTER INDUCTION; IRINOTECAN; NEW MODEL; NUCLEAR FACTORS; OPTIMAL SCHEME; OVER-EXPRESSION; PHARMACOKINETICSPHARMACODYNAMICS; SINGLE-AGENT; THERAPEUTIC STRATEGY; THERAPEUTICS OPTIMIZATION;

CELL CULTURE; CELL PROLIFERATION; DISEASES; MATHEMATICAL MODELS; MOLECULAR MODELING; NUCLEIC ACIDS;

OPTIMIZATION;

EID: 79953190719     PISSN: 08939659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.aml.2011.02.017     Document Type: Article

References (23)

1. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 1 2002 48 58 (Pubitemid 37328807)
2. R.H. Mathijssen, R.J. van Alphen, J. Verweij, W.J. Loos, K. Nooter, and G. Stoter Clinical pharmacokinetics and metabolism of irinotecan (CPT11) Clin. Cancer Res. 7 8 2001 2182 2194 (Pubitemid 32751614)
3. Y. Takeba, S. Sekine, T. Kumai, N. Matsumoto, S. Nakaya, and Y. Tsuzuki Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells Biol. Pharm. Bull. 30 8 2007 1400 1406 (Pubitemid 47282184)
4. Y. Bessho, T. Oguri, H. Achiwa, H. Muramatsu, H. Maeda, T. Niimi, S. Sato, and R. Ueda Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer Cancer Sci. 97 3 2006 192 198
5. L. Candeil, I. Gourdier, D. Peyron, N. Vezzio, V. Copois, and F. Bibeau ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases Int. J. Cancer 109 6 2004 848 854 (Pubitemid 38500741)
6. A. Ballesta, S. Dulong, C. Abbara, B. Cohen, A. Okyar, J. Clairambault, F. Levi, A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery, PLoS Comput. Biol. (submitted for publication).
7. Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond Nat. Rev. Cancer 6 10 2006 789 802 (Pubitemid 44450467)
8. Y. Habraken, and J. Piette NF-kappaB activation by double-strand breaks Biochem. Pharmacol. 72 9 2006 1132 1141 Epub 2006 Sep 11
9. T.T. Huang, S.M. Wuerzberger-Davis, B.J. Seufzer, S.D. Shumway, T. Kurama, D.A. Boothman, and S. Miyamoto NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events J. Biol. Chem. 275 13 2000 9501 9509 (Pubitemid 30185179)
10. V. Bottero, V. Busuttil, A. Loubat, N. Magna, J.L. Fischel, G. Milano, and J.F. Peyron Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells Cancer Res. 61 21 2001 7785 7791 (Pubitemid 33049365)
11. M. Bentires-Alj, V. Barbu, M. Fillet, A. Chariot, B. Relic, N. Jacobs, J. Gielen, M.P. Merville, and V. Bours NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells Oncogene 22 1 2003 90 97 (Pubitemid 36152887)
12. N. Kameyama, S. Arisawa, J. Ueyama, S. Kagota, K. Shinozuka, and A. Hattori Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes Biochim. Biophys. Acta 1782 5 2008 355 360 Epub 2008 Mar 4
13. T. Adachi, H. Nakagawa, I. Chung, Y. Hagiya, K. Hoshijima, N. Noguchi, M.T. Kuo, and T. Ishikawa Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress J. Exp. Ther. Oncol. 6 4 2007 335 348 (Pubitemid 350104822)
14. A. Hayashi, H. Suzuki, K. Itoh, M. Yamamoto, and Y. Sugiyama Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts Biochem. Biophys. Res. Commun. 310 3 2003 824 829 (Pubitemid 37188696)
15. J.M. Maher, X. Cheng, A.L. Slitt, M.Z. Dieter, and C.D. Klaassen Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver Drug Metab. Dispos. 33 7 2005 956 962 Epub 2005 Apr 15 (Pubitemid 41002777)
16. I.M. Copple, C.E. Goldring, N.R. Kitteringham, and B.K. Park The keap1-nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity Handb. Exp. Pharmacol. 196 2010 233 266
17. S. Sebens, A. Arlt, and H. Schafer NF-kappaB as a molecular target in the therapy of pancreatic carcinoma Recent Results Cancer Res. 177 2008 151 164
18. J.C. Cusack Jr., R. Liu, and A.S. Baldwin Jr. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation Cancer Res. 60 9 2000 2323 2330 (Pubitemid 30262414)
19. J. Guo, U.N. Verma, R.B. Gaynor, E.P. Frenkel, and C.R. Becerra Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit Clin. Cancer Res. 10 10 2004 3333 3341 (Pubitemid 38685438)
20. F. Levi, A. Okyar, S. Dulong, P.F. Innominato, and J. Clairambault Circadian timing in cancer treatments Annu. Rev. Pharmacol. Toxicol. 50 2010 377 421
21. N. Hansen The CMA evolution strategy: a comparing review. Towards a new evolutionary computation Advances on Estimation of Distribution Algorithms 2006 Springer 75 102 (Pubitemid 44856937)
22. C. Basdevant, J. Clairambault, and F. Levi Optimisation of time-scheduled regimen for anti-cancer drug infusion ESAIM:M2AN 39 6 2005 1069 1086 (Pubitemid 43057978)
23. K.T. Luu, and J.A. Uchizono P-glycoprotein induction and tumor cell-kill dynamics in response to differential doxorubicin dosing strategies: a theoretical pharmacodynamic model Pharm. Res. 22 5 2005 710 715 Epub 2005 May 17 (Pubitemid 40768581)